open access
Tumour-induced osteomalacia (TIO)
Affiliations- Department and Clinic of Endocrinology, Diabetology, and Isotope Therapy of Wrocław Medical University, Wroclaw, Poland
- Department of Endocrinology, Diabetology, and Isotope Therapy, University Hospital of Wroclaw, Wroclaw, Poland
open access
Abstract
Not required for Clinical Vignettes.
Abstract
Not required for Clinical Vignettes.
Keywords
TIO; hypophosphataemic osteomalacia; FGF23; hypophosphataemia
Supp./Additional Files (1)
About this articleTitle
Tumour-induced osteomalacia (TIO)
Journal
Issue
Article type
Clinical vignette
Pages
903-904
Published online
2022-06-20
Page views
4012
Article views/downloads
528
DOI
Pubmed
Bibliographic record
Endokrynol Pol 2022;73(5):903-904.
Keywords
TIO
hypophosphataemic osteomalacia
FGF23
hypophosphataemia
Authors
Agnieszka Molendowska
Joanna Jakubowska
Diana Jędrzejuk
Jadwiga Szymczak
References (4)- Fukumoto S. Diagnostic Modalities for FGF23-Producing Tumors in Patients with Tumor-Induced Osteomalacia. Endocrinol Metab (Seoul). 2014; 29(2): 136–143.
- Dahir K, Zanchetta MB, Stanciu I, et al. Diagnosis and Management of Tumor-induced Osteomalacia: Perspectives From Clinical Experience. J Endocr Soc. 2021; 5(9): bvab099.
- Endo I, Fukumoto S, Ozono K, et al. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone. 2008; 42(6): 1235–1239.
- Chong WH, Molinolo AA, Chen CC, et al. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011; 18(3): R53–R77.
